Contrary to the hopes of its supporters, indication-based drug pricing will result in higher prices for patients who benefit the most from a given drug, higher utilization by patients who benefit least, higher overall spending, and higher manufacturer profits.
No takes yet. Share an insight, caveat, or question.
Chandra et al. (2017) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: